Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11195
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTebbutt, Niall Cen
dc.contributor.authorMurphy, Fen
dc.contributor.authorZannino, Den
dc.contributor.authorWilson, Ken
dc.contributor.authorCummins, M Men
dc.contributor.authorAbdi, Een
dc.contributor.authorStrickland, A Hen
dc.contributor.authorLowenthal, R Men
dc.contributor.authorMarx, Gen
dc.contributor.authorKarapetis, Cen
dc.contributor.authorShannon, Jen
dc.contributor.authorGoldstein, David Ben
dc.contributor.authorNayagam, S Sen
dc.contributor.authorBlum, Ren
dc.contributor.authorChantrill, Len
dc.contributor.authorSimes, R Jen
dc.contributor.authorPrice, Timothy Jen
dc.date.accessioned2015-05-16T00:47:00Z
dc.date.available2015-05-16T00:47:00Z
dc.date.issued2011-01-27en
dc.identifier.citationAnnals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo 2011; 22(8): 1834-8en
dc.identifier.govdoc21273347en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11195en
dc.description.abstractBevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab.We recorded grade 3, 4, or 5 ATE events and other data (including age, baseline cardiovascular risk factors, history of ATE, and aspirin use) from 471 patients with metastatic colorectal cancer in the MAX (Mitomycin, Avastin, Xeloda) trial of capecitabine monotherapy versus capecitabine with bevacizumab with or without mitomycin C.Bevacizumab-treated patients had 12 grade 3, 4, or 5 ATEs (3.8% incidence). ATEs occurred in 2.1% of patients >65 years, 5% of those with a history of ATE, and 5% of those with cardiac risk factors. Age, history of ATE, or vascular risk factors did not increase risk. Aspirin users had a higher incidence than nonusers (8.9% versus 2.7%) but had higher rates of vascular risk factors.Bevacizumab was associated with a modestly higher risk of ATE, but safety was not significantly worse in older patients or patients with a history of ATE or vascular risk factors. The effect of aspirin in preventing ATE in patients receiving bevacizumab could not be determined from this study.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAge Factorsen
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAngiogenesis Inhibitors.adverse effects.therapeutic useen
dc.subject.otherAntibodies, Monoclonal, Humanized.adverse effects.therapeutic useen
dc.subject.otherAspirin.therapeutic useen
dc.subject.otherColorectal Neoplasms.drug therapy.pathologyen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherNeoplasm Stagingen
dc.subject.otherRisk Factorsen
dc.subject.otherThromboembolism.etiologyen
dc.titleRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.en
dc.typeJournal Articleen
dc.identifier.journaltitleAnnals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.identifier.affiliationniall.tebbutt@ludwig.edu.auen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Melbourne, Australiaen
dc.identifier.doi10.1093/annonc/mdq702en
dc.description.pages1834-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21273347en
dc.contributor.corpauthorAustralasian Gastro-Intestinal Trials Groupen
dc.type.austinJournal Articleen
local.name.researcherTebbutt, Niall C
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.